Disc Medicine (IRON) Cash & Equivalents (2020 - 2026)

Disc Medicine (IRON) has 7 years of Cash & Equivalents data on file, last reported at $88.9 million in Q1 2026.

• Quarterly Cash & Equivalents fell 27.52% year-over-year to $88.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.9 million (down 27.52% YoY) and the FY2025 annual result came in at $91.1 million, down 52.64% from the prior year.
• Cash & Equivalents fell to $88.9 million in Q1 2026 per IRON's latest filing, from $91.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $377.6 million in Q2 2023 and bottomed at $88.9 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $192.4 million (2024), against an average of $202.8 million.
• The widest annual swing landed in 2023, when Cash & Equivalents jumped 264.31%; it then tumbled 64.19% in 2025.
• Tracing IRON's Cash & Equivalents over 5 years: stood at $194.6 million in 2022, then jumped by 85.18% to $360.4 million in 2023, then slumped by 46.6% to $192.4 million in 2024, then sank by 52.64% to $91.1 million in 2025, then fell by 2.45% to $88.9 million in 2026.
• Per Business Quant, the three latest IRON Cash & Equivalents figures stand at $88.9 million (Q1 2026), $91.1 million (Q4 2025), and $140.7 million (Q3 2025).

Peer Comparison